000			01536 a2200457 4500
005			20250515211651.0
264		0	_c20100803
008			201008s 0 0 eng d
022			_a1556-0961
024	7		_a10.1007/s12028-008-9156-x _2doi
040			_aNLM _beng _cNLM
100	1		_aGrof, Tina M
245	0	0	_aEvaluating the use of dexmedetomidine in neurocritical care patients. _h[electronic resource]
260			_bNeurocritical care _cJun 2010
300			_a356-61 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAdolescent
650	0	4	_aAdrenergic alpha-Agonists _xadverse effects
650	0	4	_aAdult
650	0	4	_aArousal _xdrug effects
650	0	4	_aBlood Pressure _xdrug effects
650	0	4	_aConscious Sedation _xmethods
650	0	4	_aCritical Care _xmethods
650	0	4	_aDexmedetomidine _xadverse effects
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aHeart Rate _xdrug effects
650	0	4	_aHemodynamics _xdrug effects
650	0	4	_aHumans
650	0	4	_aHypnotics and Sedatives _xadverse effects
650	0	4	_aInfusions, Intravenous
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProspective Studies
650	0	4	_aPsychomotor Agitation _xdrug therapy
650	0	4	_aYoung Adult
700	1		_aBledsoe, Kathleen A
773	0		_tNeurocritical care _gvol. 12 _gno. 3 _gp. 356-61
856	4	0	_uhttps://doi.org/10.1007/s12028-008-9156-x _zAvailable from publisher's website
999			_c19583954 _d19583954